Indolent B-cell non-Hodgkin lymphoma
MONDO:0017594Also known as: indolent B-cell NHL, B cell lymphoma, indolent, indolent B cell lymphoma
3037 clinical trials for this condition and its sub-types, 69 tagged with Indolent B-cell non-Hodgkin lymphoma itself.
Follow this condition to get notified about new trialsWhere it sits in the disease tree
Browse by category →Sub-types of Indolent B-cell non-Hodgkin lymphoma
-
Follicular lymphoma 590 trials
-
B-cell chronic lymphocytic leukemia 509 trials · 538 incl. sub-types
2 sub-types
- Chronic lymphocytic leukemia/small lymphocytic lymphoma 108 trials · 109 incl. sub-types Sub-types →
- Hairy cell leukemia 40 trials Sub-types →
-
Marginal zone lymphoma 213 trials · 232 incl. sub-types
4 sub-types
- MALT lymphoma 30 trials · 31 incl. sub-types Sub-types →
- Splenic marginal zone lymphoma 20 trials
- Nodal marginal zone B-cell lymphoma 16 trials
- Splenic diffuse red pulp small B-cell lymphoma 0 trials
-
Waldenstrom macroglobulinemia 136 trials
2 sub-types
- Macroglobulinemia, Waldenstrom, 1 2 trials
- Macroglobulinemia, Waldenstrom, 2 0 trials
-
Indolent primary cutaneous B-cell lymphoma 1 trial · 2 incl. sub-types
2 sub-types
Most studied deeper sub-types
-
New drug combo shows promise for Hard-to-Treat lymphomas
Disease control Stopped earlyThis study tested a combination of two drugs, favezelimab and pembrolizumab, in 137 people with certain blood cancers like Hodgkin lymphoma and B-cell lymphoma. The goal was to see if the combination was safe and could shrink tumors. The study also looked at each drug alone in so…
Phase 1/2 • Sponsor: Merck Sharp & Dohme LLC • Aim: Disease control
Last updated Jul 30, 2026 00:00 UTC
-
Targeted drug combo shows promise in blood cancer transplant study
Disease control Stopped earlyThis study tested whether adding the targeted drug inotuzumab ozogamicin before and after a stem cell transplant could help control leukemia and lymphoma. It included 15 people aged 12 to 75 with certain blood cancers. The study was stopped early, but researchers looked at safety…
Phase 2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 12:07 UTC
-
Experimental cell therapy for tough blood cancers put on hold
Disease control Stopped earlyThis early-stage study tested a new treatment called CNTY-101 for people with B-cell cancers that came back or didn't respond to other therapies. The main goals were to find a safe dose and see if the treatment could shrink tumors. The study was stopped early, so results are limi…
Phase 1 • Sponsor: Century Therapeutics, Inc. • Aim: Disease control
Last updated Jun 27, 2026 08:05 UTC
-
Drug combo aims to control Slow-Growing lymphoma without chemo
Disease control Stopped earlyThis phase 2 study tested a combination of two drugs, lenalidomide and rituximab, in 30 people with previously untreated indolent non-Hodgkin's lymphoma. The goal was to see how well the drugs worked together to shrink or control the cancer. Participants took lenalidomide daily f…
Phase 2 • Sponsor: University of California, Davis • Aim: Disease control
Last updated Jun 27, 2026 07:59 UTC
-
Keytruda trial for untreated lymphoma halted early
Disease control Stopped earlyThis phase II study tested the immunotherapy drug pembrolizumab (Keytruda) in 9 people with untreated follicular lymphoma or marginal zone lymphoma. The goal was to see if the drug could shrink tumors or slow the disease. However, the trial was terminated early, so we have very l…
Phase 2 • Sponsor: University of Washington • Aim: Disease control
Last updated Jun 27, 2026 07:57 UTC